Peer-Reviewed Publication
NPJ Aging2025;12(1):16.December 23, 2025Journal Article
Recommendations for biomarker data collection in clinical trials by longevity biotechnology companies.
Chiara M S Herzog1,2, Jesse R Poganik3, Nicola Boekstein4, Kristen Fortney5, James G Peyer6, Jim Mellon7, Risa Starr4, Nir Barzilai8,9, Mahdi Moqri10,11
1Department of Twin Research and Genetic Epidemiology, School of Life Course and Population Sciences, Faculty of Medicine and Life Sciences, King's College London, London, UK.
2European Translational Oncology Prevention and Screening Institute, Universität Innsbruck, Innsbruck, Austria.
3Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
4Longevity Biotechnology Association, Ramsey, MN, USA.
5BioAge Labs, Emeryville, CA, USA.
6Cambrian Bio, New York, NY, USA.
7Juvenescence, Ramsey, MN, USA.
8Longevity Biotechnology Association, Ramsey, MN, USA. nir.barzilai@einsteinmed.edu.
9Institute for Aging Research, Albert Einstein College of Medicine, Bronx, NY, USA. nir.barzilai@einsteinmed.edu.
10Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. mmoqri@bwh.harvard.edu.
11Department of Genetics, School of Medicine, Stanford University, Stanford, CA, USA. mmoqri@bwh.harvard.edu.
Abstract
Biomarkers of aging have the potential to transform geroscience clinical trials because of their broad applications in stratifying participants, prioritizing interventions, and monitoring responses to geroprotectors. As longevity biotechnology companies (LBCs) continue to plan and launch innovative clinical trials, standard practices in collecting data and applying biomarkers of aging will allow t…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans